Amino acid catabolism in liver : glycine and glutamine

The liver removes substantial quantities of glycine and glutamine from the circulation in animals ingesting high-protein diets. Glycine and glutamine, however, do not accumulate in liver tissue during a protein meal, and in fact, their hepatic concentrations may actually decrease. Thus, there appears to be an activation of hepatic glycine and glutamine catabolism at this time. Glycine and glutamine catabolism are initiated within mitochondria via the glycine cleavage system and glutaminase, respectively. Rapid activation of these enzymes has been demonstrated in intact mitochondria from glucagon-injected rats. However, it was unknown whether similar activations occur as part of an hepatic physiological response to protein intake. In this thesis, glycine and glutamine catabolism have been extensively studied in intact mitochondria from rats fed on a high-protein diet or given a single high-protein meal. -- It was discovered that intact liver mitochondria from rats fed on a high-protein diet for six days catabolise glycine and glutamine at enhanced rates compared to mitochondria from rats fed a normal-protein diet. Glycine and glutamine catabolism were also stimulated in normal- protein-fed rats if they ingested a single high-protein meal for 2 hours before being killed. Thus, flux through the glycine cleavage system and through glutaminase is able to respond rapidly, according to the protein intake experienced during an individual meal. Investigations using whole cells or isolated, intact liver from such animals allow similar conclusions. Thus it is proposed that activation of the glycine cleavage system and glutaminase is a normal hepatic response in animals ingesting a high-protein meal

Anti-diabetic or anti-hypertensive dietary supplement

An anti-diabetic or anti-hypertensive fish protein hydrolysate is provided, in which the fish is of the genus Salmo or Oncorhynchus, and wherein the fish protein is hydrolysed by a metalloendopeptidase obtainable from Bacillus amyloliquefaciens. Methods of making and methods for using such fish protein hydrolysates are also provided

Compositions comprising Porphyra and methods of making and using thereof

The disclosed subject matter generally relates to compositions comprising Porphyra, as well as to methods of making and using such composition

Chromium-fatty acid compounds and methods of making and using thereof

Disclosed are compounds comprising one or more chromium atoms bonded to one or more fatty acids. Also disclosed are nutritional supplements, pharmaceutical formulations, delivery devices, and foodstuffs comprising the disclosed compounds. Methods of using the disclosed compounds and compositions to improve health are also disclose

Anti-hypertensive dietary supplement

An anti-hypertensive fish protein hydrolysate is provided, wherein the fish is of the genus Salmo or Oncorhynchus, and wherein the fish protein hydrolysate comprises at least 1 peptide selected from the group consisting of: Leu-Ala-Phe, Leu-Tbr-Phe, Ile-Ile-Phe, Leu-Ala-Tyr, Ile-Ala-Tyr, ValPhe- Tyr, Tyr-Ala-Tyr, Val-Leu-Trp, Ile-Ala-Trp, Tyr-AlaLeu and Tyr-Asn-Arg. Methods of making and methods for using such fish protein hydrolysates are also provided. The invention concerns an anti-hypertensive composition, a method of producing such composition and a dietary supplement made by way of such a method

Anti-hypertensive dietary supplement derived from Salmo or Oncorhynchus protein hydrolysates

An anti-hypertensive fish protein hydrolysate is provided, wherein the fish is of the genus Salmo or Oncorhynchus, and wherein the fish protein hydrolysate that is prepared using bacillolysm from Bacillus stearothermophilus comprises at least one peptide selected from the group consisting of Leu-Ala-Phe, Leu-Thr-Phe, Ile-Ile-Phe, Leu-Ala-Tyr, Ile-Ala-Tyr, Val-Phe-Tyr, Tyr-Ala-Tyr, Val-Leu-Trp, Ile-Ala-Trp, Tyr- Ala-Leu and Tyr-Asn-Arg Method of making and methods for using such fish protein hydrolysates are also provided

Ascophyllum compositions and methods

The invention provides extracts of brown seaweed of the genus Ascophyllum that have valuable pharmacological properties. In particular, compositions of the invention are useful for e.g.: inhibiting alpha-glucosidase activity; preventing or treating conditions mediated by alpha-glucosidase activity; reducing blood glucose levels; preventing or treating diabetes; modulating glucose uptake in adipocytes; preventing or treating obesity; scavenging free radicals; stimulating the immune system; activating macrophages; preventing or treating condition mediated by macrophage activation; and modulating nitric oxide production by macrophages. Methods for using the Ascophyllum extracts of the invention are provided, as are kits comprising Ascophyllum extracts of the invention and instructions for using the extracts

Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry.

BACKGROUND: Low-frequency variants play an important role in breast cancer (BC) susceptibility. Gene-based methods can increase power by combining multiple variants in the same gene and help identify target genes. METHODS: We evaluated the potential of gene-based aggregation in the Breast Cancer Association Consortium cohorts including 83,471 cases and 59,199 controls. Low-frequency variants were aggregated for individual genes' coding and regulatory regions. Association results in European ancestry samples were compared to single-marker association results in the same cohort. Gene-based associations were also combined in meta-analysis across individuals with European, Asian, African, and Latin American and Hispanic ancestry. RESULTS: In European ancestry samples, 14 genes were significantly associated (q < 0.05) with BC. Of those, two genes, FMNL3 (P = 6.11 × 10-6) and AC058822.1 (P = 1.47 × 10-4), represent new associations. High FMNL3 expression has previously been linked to poor prognosis in several other cancers. Meta-analysis of samples with diverse ancestry discovered further associations including established candidate genes ESR1 and CBLB. Furthermore, literature review and database query found further support for a biologically plausible link with cancer for genes CBLB, FMNL3, FGFR2, LSP1, MAP3K1, and SRGAP2C. CONCLUSIONS: Using extended gene-based aggregation tests including coding and regulatory variation, we report identification of plausible target genes for previously identified single-marker associations with BC as well as the discovery of novel genes implicated in BC development. Including multi ancestral cohorts in this study enabled the identification of otherwise missed disease associations as ESR1 (P = 1.31 × 10-5), demonstrating the importance of diversifying study cohorts